Additionally, a phase 3 clinical trial has been registered recently for cytokines therapy on COVID-19 patients, evaluating the efficacy and safety of treatment with IL-2 or inhibitor of IL-17 (ClinicalTrials.gov Identifier: NCT04724629). Here, IL2 is linked to COVID-19.